OR9A2

Across TCGA pan-cancer cohorts, OR9A2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR9A2 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher OR9A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR9A2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

BRCA, HNSC, and LIHC are the cancer types where OR9A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.093	0.950	<.001	36	view →
HNSC	OS	Median	All	0.156	0.710	.002	30	view →
LIHC	DFS	Median	All	0.099	0.555	.007	18	view →
LGG	DFS	Median	All	0.185	0.832	<.001	12	view →
SKCM	DFS	Median	III,IV	0.870	0.573	.024	3	view →
UCEC	DFS	Median	All	1.000	0.625	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR9A2–BRCA (DFS)

Open the BRCA breakdown →